Bushfield M, Murphy G J, Lavan B E, Parker P J, Hruby V J, Milligan G, Houslay M D
Department of Biochemistry, University of Glasgow, Scotland, U.K.
Biochem J. 1990 Jun 1;268(2):449-57. doi: 10.1042/bj2680449.
Hepatocytes contain the Gi2 and Gi3 forms of the 'Gi-family' of guanine-nucleotide-binding proteins (G-proteins), but not Gi1. The anti-peptide antisera AS7 and I3B were shown to immunoprecipitate Gi2 and Gi3 selectively, and the antiserum CS1 immunoprecipitated the stimulatory G-protein Gs. Treatment of intact, 32P-labelled hepatocytes with one of glucagon, TH-glucagon ([1-N-alpha-trinitrophenylhistidine, 12-homoarginine]glucagon), Arg-vasopressin, angiotensin-II, the phorbol ester TPA (12-O-tetradecanoylphorbol 13-acetate) and 8-bromo-cyclic AMP elicited a time- and dose-dependent increase in the labelling of the alpha-subunit of immunoprecipitated Gi2 which paralleled the loss of ability of low concentrations of the non-hydrolysable GTP analogue guanosine 5'-[beta gamma-imido]triphosphate (p[NH]ppG) to inhibit forskolin-stimulated adenylate cyclase activity ('Gi'-function). The immunoprecipitation of phosphorylated Gi-2 alpha-subunit by the antiserum AS7 was blocked in a dose-dependent fashion by the inclusion of the C-terminal decapeptide of transducin, but not that of Gz (a 'Gi-like' G-protein which lacks the C-terminal cysteine group which is ADP-ribosylated by pertussis toxin in other members of the Gi family), in the immunoprecipitation assay. No labelling of the alpha-subunits of either Gi3 or Gs was observed. alpha-Gi2 was labelled in the basal state and this did not change over 15 min in the absence of ligand addition. In contrast to the monophasic dose-effect curves seen with vasopressin, angiotensin and TPA, the dose-effect curve for the glucagon-mediated increase in the labelling of alpha-Gi2 was markedly biphasic where the loss of Gi function paralleled the high-affinity component of the labelling of alpha-Gi2 caused by glucagon. TPA, TH-glucagon, angiotensin-II and vasopressin achieved similar maximal increases in the labelling of alpha-Gi2, which was approximately half that found after treatment of hepatocytes with either high glucagon concentrations (1 microM) or 8-bromocyclic AMP. Analysis of the phosphoamino acid content of immunoprecipitated alpha-Gi2 showed the presence of phosphoserine only. Incubation of hepatocyte membranes with [gamma-32P]ATP and purified protein kinase C, but not protein kinase A, led to the incorporation of label into immunoprecipitated alpha-Gi2. This labelling was abolished if membranes were obtained from cells which had received prior treatment with ligands shown to cause the phosphorylation of alpha-Gi2 in intact cells. We suggest that there are two possible sites for the phosphorylation of alpha-Gi2; one for C-kinase and the other for an unidentified kinase whose action is triggered by A-kinase activation.
肝细胞含有鸟嘌呤核苷酸结合蛋白(G蛋白)“Gi家族”的Gi2和Gi3形式,但不含Gi1。抗肽抗血清AS7和I3B被证明能选择性免疫沉淀Gi2和Gi3,抗血清CS1免疫沉淀刺激性G蛋白Gs。用胰高血糖素、TH-胰高血糖素([1-N-α-三硝基苯基组氨酸,12-高精氨酸]胰高血糖素)、精氨酸加压素、血管紧张素-II、佛波酯TPA(12-O-十四烷酰佛波醇13-乙酸酯)和8-溴环磷酸腺苷中的一种处理完整的、32P标记的肝细胞,会引起免疫沉淀的Gi2α亚基标记的时间和剂量依赖性增加,这与低浓度的不可水解GTP类似物鸟苷5'-[βγ-亚氨基]三磷酸(p[NH]ppG)抑制福司可林刺激的腺苷酸环化酶活性(“Gi功能”)的能力丧失平行。抗血清AS7对磷酸化的Gi-2α亚基的免疫沉淀在免疫沉淀试验中被转导蛋白的C末端十肽以剂量依赖性方式阻断,但Gz(一种“Gi样”G蛋白,缺乏Gi家族其他成员中被百日咳毒素ADP-核糖基化的C末端半胱氨酸基团)的C末端十肽则不会。未观察到Gi3或Gs的α亚基有标记。α-Gi2在基础状态下被标记,在不添加配体的情况下15分钟内没有变化。与加压素、血管紧张素和TPA所见的单相剂量效应曲线不同,胰高血糖素介导的α-Gi2标记增加的剂量效应曲线明显呈双相,其中Gi功能的丧失与胰高血糖素引起的α-Gi2标记的高亲和力成分平行。TPA、TH-胰高血糖素、血管紧张素-II和加压素在α-Gi2标记上实现了类似的最大增加,这大约是用高浓度胰高血糖素(1μM)或8-溴环磷酸腺苷处理肝细胞后发现的增加量的一半。对免疫沉淀的α-Gi2的磷酸氨基酸含量分析表明仅存在磷酸丝氨酸。用[γ-32P]ATP和纯化的蛋白激酶C孵育肝细胞膜,但不与蛋白激酶A孵育,导致标记掺入免疫沉淀的α-Gi2中。如果膜是从预先用已证明能在完整细胞中引起α-Gi2磷酸化的配体处理过的细胞中获得的,则这种标记会被消除。我们认为α-Gi2有两个可能的磷酸化位点;一个是C激酶的位点,另一个是其作用由A激酶激活触发的未鉴定激酶的位点。